An IL-1beta binding molecule, such as a human antibody, comprising both heavy (vH) and light chain (VL) variable domains in which said IL-1beta binding molecule comprises at least one antigen binding site comprising: (a) an immunoglobulin heavy chain variable domain which comprises in sequence hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Val-Tyr-Gly-Met-Asn (VYGMN), said CDR2 having the amino acid sequence Ile-Ile-Trp-Tyr-Asp-Gly-Asp-Asn-Gln-Tyr-Tyr-Ala-Asp-Ser-Val-Lys-Gly (IIWYDGDNQYYADSVKG), and said CDR3 having the amino acid sequence Asp-Leu-Arg-Thr-Gly-Pro (DLRTGP); and (b) an immunoglobulin light chain variable domain which comprises in sequence hypervariable regions CDR1', CDR2' and CDR3', said CDR1' having the amino acid sequence Arg-Ala-Ser-Gln-Ser-Ile-Gly-Ser-Ser-Leu-His (RASQSIGSSLH), said CDR2' having the amino acid sequence Ala-Ser-Gln-Ser-Phe-Ser (ASQFS), and said CDR3' having the amino acid sequence His-Gln-Ser-Ser-Leu-Pro (HQSSLP); and direct equivalents thereof.
Antibodies to human IL-1beta